Abstract
Introduction Despite continuous parathyroid hormone (PTH) exposure potentially accelerating bone resorption, intermittent PTH administration has shown anabolic effects on bone microarchitecture. This study investigates the therapeutic impacts of two PTH analogs, rhPTH(1-34) and dimeric R25CPTH(1-34) on bone regeneration and osseointegration in a postmenopausal osteoporosis animal model.
Methods Twelve female beagles, osteoporotic post-ovariectomy, underwent implant surgeries. Animals were divided into three groups: control, daily rhPTH(1-34) injection, and daily dimeric R25CPTH(1-34) injection. After 10 weeks, bone regeneration and implant osseointegration were evaluated using micro-CT, histological/histomorphometric analyses, and serum biochemical analysis.
Results While the rhPTH(1-34) group demonstrated improved microarchitectural characteristics, such as BMD, BV, trabecular metrics, and osseointegration degree, the dimeric R25CPTH(1-34) group showed similarly enhanced anabolic effects around the titanium implants, albeit these were less pronounced than the rhPTH(1-34), yet significantly better than the control group. Histologic and TRAP assays revealed that both PTH analogs significantly promoted bone regeneration and remodeling, especially in artificially created bone defects.
Conclusion This study demonstrated the therapeutic effects of rhPTH(1-34) and dimeric R25CPTH(1-34) on bone regeneration and titanium osseointegration in a beagle model with osteoporosis.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
The terms (Cys25)PTH(1-84) and Dimeric R25CPTH(1-34) were clarified. Figure and figure legends were corrected. Compared to rhPTH(1-34), the effectiveness of (Cys25)PTH(1-84) were discussed biologically and clinically. Materials and methods were placed after the discussion section in accordance with the format of the elife journal. For a better and initial understanding, a description of each experimental group has been added to the Results section as follow. Thank you again for your valuable comments.
